Parental Medication Education for Preventing Medication Errors After NICU Discharge
Trial Summary
What is the purpose of this trial?
This is a randomized controlled study of parents of children to be discharged from the neonatal intensive care unit at Bellevue and Elmhurst hospitals. A total of 425 subjects will be recruited across two sites over preparatory phases and two primary study phases.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment HELPix, HELPix+Tech for preventing medication errors after NICU discharge?
Is the Parental Medication Education program safe for humans?
How does the treatment HELPix, HELPix+Tech differ from other treatments for preventing medication errors after NICU discharge?
Research Team
Hsiang Sharon Yin
Principal Investigator
NYU Langone
Eligibility Criteria
This trial is for parents over 18, who speak English or Spanish, and are the primary caregivers administering at least one daily liquid medication to their child after discharge from the neonatal intensive care unit. Participants must have internet access, a mobile phone that can receive texts, and be able to return for follow-up visits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preparatory Phase
Preparatory activities for the study, including recruitment and initial setup
Intervention Phase
Parents receive usual care, HELPix, and/or HELPix+Tech interventions to support safe medication use
Follow-up
Participants are monitored for safety and effectiveness after intervention
Treatment Details
Interventions
- HELPix
- HELPix+Tech
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor